NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

TPST

Tempest Therapeutics Inc

May 08 • 04:00PM ET

6.85

Dollar change +0.43
Percentage change 6.70	%

Healthcare • Biotechnology • USA • NASD

Peers: IMMP ADAP ATNM AGEN AFMD HOOK KALA COGT ONCY MRKR

| Held by: VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-19.54	Insider Own	9.21%	Shs Outstand	3.38M	Perf Week	0.00%
Market Cap	25.04M	Forward P/E	-	EPS next Y	-15.76	Insider Trans	0.00%	Shs Float	3.32M	Perf Month	5.26%
Income	-41.84M	PEG	-	EPS next Q	-3.29	Inst Own	6.00%	Short Float	3.31%	Perf Quarter	-42.04%
Sales	0.00M	P/S	-	EPS this Y	29.93%	Inst Trans	-	Short Ratio	1.79	Perf Half Y	-44.01%
Book/sh	5.65	P/B	1.21	EPS next Y	-15.32%	ROA	-87.51%	Short Interest	0.11M	Perf Year	-85.87%
Cash/sh	8.28	P/C	0.83	EPS next 5Y	11.82%	ROE	-182.35%	52W Range	5.35 - 47.45	Perf YTD	-36.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	50.16%	ROI	-153.45%	52W High	-85.56%	Beta	-1.90
Dividend TTM	-	Quick Ratio	2.21	Sales past 5Y	0.00%	Gross Margin	-	52W Low	28.05%	ATR (14)	0.64
Dividend Ex-Date	-	Current Ratio	2.21	EPS Y/Y TTM	-220.54%	Oper. Margin	-	RSI (14)	40.63	Volatility	6.99% 10.38%
Employees	25	Debt/Eq	0.80	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.33	Target Price	94.00
Option/Short	No / Yes	LT Debt/Eq	0.43	EPS Q/Q	9.72%	Payout	-	Rel Volume	0.80	Prev Close	6.42
Sales Surprise	-	EPS Surprise	-23.08%	Sales Q/Q	-	Earnings	Mar 27 AMC	Avg Volume	61.55K	Price	6.85
SMA20	-3.74%	SMA50	-22.51%	SMA200	-47.45%	Trades		Volume	49,347	Change	6.70%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Apr-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$13
Feb-08-24	Initiated	Jefferies	Buy	$15

Apr-28-25 04:05PM	Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting (GlobeNewswire) -6.26%
Apr-21-25 08:00AM	Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP (GlobeNewswire)
Apr-10-25 11:05AM	TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up (Zacks) -18.04%
Apr-09-25 04:30PM	Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value (GlobeNewswire) +9.87%
Mar-27-25 04:10PM	Tempest Reports Year End 2024 Financial Results and Provides Business Update (GlobeNewswire) -8.08%
04:30PM	Loading…
Mar-25-25 04:30PM	Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-13-25 08:00AM	FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP) (GlobeNewswire)
Feb-10-25 08:00AM	Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (GlobeNewswire)
Feb-07-25 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-06-25 08:00AM	Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) (GlobeNewswire)
Dec-06-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-24 09:00PM	A Reverse Aging Gurus Trail of Failed Businesses (The Wall Street Journal)
Nov-25-24 04:30PM	Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-12-24 04:21PM	Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -10.50%
08:00AM	Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma (GlobeNewswire)
07:01AM	Loading…
Oct-10-24 07:01AM	Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial (GlobeNewswire) -18.52%
07:00AM	Tempest Extends Limited Duration Stockholder Rights Plan (GlobeNewswire)
Sep-20-24 04:30PM	Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-18-24 08:00AM	Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs (GlobeNewswire) -6.62%
Sep-05-24 08:00AM	Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +5.04%
Aug-23-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-21-24 08:00AM	Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance (GlobeNewswire)
Aug-15-24 08:00AM	Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma (GlobeNewswire) +30.25%
Aug-08-24 04:56PM	Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -14.18%
Jun-20-24 08:13AM	Why Is Tempest Therapeutics (TPST) Stock Up 45% Today? (InvestorPlace) -29.47%
08:00AM	Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm (GlobeNewswire)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-18-24 06:22PM	Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Jun-07-24 04:30AM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-21-24 08:00AM	Tempest to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:29PM	Loading…
May-09-24 04:29PM	Tempest Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.34%
Apr-26-24 04:05PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-09-24 08:00AM	Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting (GlobeNewswire)
Apr-04-24 08:00AM	Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications (GlobeNewswire) -12.20%
Mar-19-24 09:53PM	TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
04:25PM	Tempest Reports Year End 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 08:00AM	Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types (GlobeNewswire)
Mar-05-24 04:30PM	Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting (GlobeNewswire) +16.09%
Feb-26-24 08:00AM	Tempest to Present at the 44th Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-02-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-05-24 04:05PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.60%
Dec-01-23 04:15PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-20-23 08:00AM	Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +9.25%
Nov-08-23 05:17PM	Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -8.74% +16.31%
Oct-12-23 08:25AM	Why Is Tempest Therapeutics (TPST) Stock Down 35% Today? (InvestorPlace) -59.26%
Oct-11-23 04:29PM	TPST Stock: 7 Things to Know About Tempest Therapeutics (InvestorPlace) +3,972.53%
08:01AM	Tempest Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
08:00AM	Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study (GlobeNewswire)
07:41AM	Why Is Tempest Therapeutics (TPST) Stock Up 325% Today? (InvestorPlace)
Oct-10-23 04:05PM	Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Sep-19-23 08:00AM	Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development (GlobeNewswire)
Sep-05-23 08:00AM	Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 04:13PM	Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +5.50%
Jul-19-23 08:00AM	Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together (GlobeNewswire)
May-31-23 04:05PM	Tempest to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -5.85% -5.88%
May-25-23 05:00PM	Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers (GlobeNewswire) -9.76%
May-19-23 04:05PM	Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-23 04:15PM	Tempest Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-23 08:00AM	Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire) +23.26%
Apr-27-23 04:58PM	Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Apr-26-23 06:41PM	Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting (GlobeNewswire) -6.74%
Apr-17-23 09:00AM	Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting (GlobeNewswire) +25.42%
Mar-22-23 05:26PM	Tempest Reports Year End 2022 Financial Results and Provides Business Update (GlobeNewswire) +6.52%
Mar-15-23 04:05PM	Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting (GlobeNewswire)
Mar-14-23 04:30PM	Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting (GlobeNewswire) +15.79%
Nov-22-22 04:05PM	Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-10-22 09:00AM	Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer (GlobeNewswire)
Nov-08-22 08:00AM	Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -12.09%
Nov-02-22 08:00AM	Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting (GlobeNewswire) +8.72%
Oct-06-22 08:00AM	Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit (GlobeNewswire)
Sep-07-22 08:00AM	Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +11.40%
Aug-15-22 08:00AM	Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +15.81%
Jul-07-22 08:00AM	Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference (GlobeNewswire) +11.93%
Jun-09-22 08:00AM	Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance (GlobeNewswire)
Jun-06-22 04:05PM	Tempest to Present at the Jefferies Healthcare Conference (GlobeNewswire) -12.50%
May-26-22 04:57PM	Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting (GlobeNewswire) -26.68%
May-13-22 08:00AM	Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights (GlobeNewswire) +5.88%
Apr-27-22 10:01AM	Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting (GlobeNewswire) +30.08%
08:00AM	Tempest Announces Private Placement Financing of $15 Million (GlobeNewswire)
Apr-08-22 01:00PM	Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting (GlobeNewswire)
Mar-29-22 04:00PM	Tempest Reports Year End 2021 Financial Results and Provides Business Update (GlobeNewswire) -7.89%
Mar-10-22 08:00AM	Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference (GlobeNewswire) -9.23%
Mar-08-22 04:30PM	Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-09-22 08:00AM	Tempest to Present at the 11th Annual SVB Leerink Healthcare Conference (GlobeNewswire)
Nov-18-21 08:00AM	Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab (GlobeNewswire)
Nov-12-21 07:00AM	Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer (GlobeNewswire)
Nov-10-21 04:05PM	Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Nov-09-21 08:00AM	Tempest to Present at Two Upcoming Investor Conferences in November (GlobeNewswire)
Nov-08-21 08:00AM	Tempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495 (GlobeNewswire)
Oct-01-21 08:00AM	Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (GlobeNewswire)
Sep-20-21 08:00AM	Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche (GlobeNewswire)
Sep-13-21 08:00AM	Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target (GlobeNewswire)
Sep-09-21 04:01PM	Tempest to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-12-21 04:01PM	Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Aug-09-21 08:00AM	Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors (GlobeNewswire) +8.09%
Jul-09-21 08:00AM	Tempest to Participate in William Blair 2021 Biotech Focus Conference (GlobeNewswire) +49.38%
Jul-01-21 04:00PM	Tempest Announces Appointment of Christine Pellizzari to its Board of Directors (GlobeNewswire)

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Versant Venture Capital VI, L.	Owner	Aug 12 '24	Proposed Sale	1.10	387,999	426,993		Aug 13 08:03 AM
Versant Venture Capital VI, L.	10% Owner	Aug 08 '24	Sale	1.35	400,000	540,040	597,940	Aug 12 08:33 PM
Versant Venture Capital VI, L.	10% Owner	Aug 12 '24	Sale	1.10	387,999	426,993	209,941	Aug 12 08:33 PM
Versant Venture Capital VI, L.	10% Owner	Aug 08 '24	Proposed Sale	18.03	400,000	7,210,532		Aug 09 03:41 PM
Brady Stephen R	President and CEO	Jul 03 '24	Buy	2.11	35,000	73,850	46,376	Jul 08 04:15 PM
Whiting Samuel	Chief Medical Officer	Jul 02 '24	Buy	2.13	4,672	9,951	9,573	Jul 03 07:35 PM
Trojanowski Justin	Corporate Controller	Jun 28 '24	Buy	2.16	7,500	16,200	22,168	Jul 02 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TPST

Tempest Therapeutics Inc

Upgrade your FINVIZ experience